跳至主要内容
临床试验/NCT02548403
NCT02548403已完成3 期

Use of Simethicone to Improve the Bowel Cleansing Effects of Polyethylene Glycol With Ascorbic Acid for Colonoscopy

Korea University Anam Hospital1 个研究点 分布在 1 个国家目标入组 260 人开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
260
试验地点
1
主要终点
the quality of the bowel preparation using Preparation Scale

研究概览

简要总结

Optimal bowel preparation is essential for colonoscopy efficacy and safety. Mucosal visualization during colonoscopy is often limited by residual stool, bubbles, bile, intraluminal fluid, and debris, which increase the risk of missing flat adenomas or other small lesions.Therefore, intestinal preparation is necessary to remove residual materials prior to endoscopy.

A combined agent, low-dose PEG with ascorbic acid (PEG-Asc), is one low-volume solution commonly used in Korea (Coolprep®; TaeJoon Pharmaceuticals, Seoul, Korea). However, practitioners have noted an increased incidence of bubble formation with this preparation method.

To the investigators knowledge, no previous study has assessed colon preparation in patients administered simethicone.

The purpose of this study was to compare the quality of bowel preparation and compliance between PEG-Asc and PEG-Asc with simethicone. The effectiveness of adding simethicone as an antifoaming agent to improve bowel cleansing for colonoscopy was evaluated in terms of bowel preparation scale and bubble score, and the compliance of both patients and endoscopists was also investigated using a questionnaire.

详细描述

  1. Study design: endoscopist-blinded, prospective, randomized controlled trial
  2. Subjects
  • A single-center, randomized, observer-blinded study was performed at Korea University Hospital in Anam. Outpatients were prospectively enrolled. Each group of the patients will receive PEG-Asc or PEG-Asc with simethicone before colonoscopy.
  1. Sampling design: Consecutive recruitment of consenting patients

  2. Variables Predictor

  3. group 1 (PEG-Asc) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure;

  4. group 2 (PEG-Asc with simethicone) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure;Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.

  5. Primary Outcome: Quality of bowel preparation [Boston Bowel Preparation Scale, bubble score]

  6. Secondary Outcome: Patients and endoscopists' compliance[Tolerability, palatability of patient, fatigue score of endoscopist]

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female patients,
  • aged between18 and 80 years undergoing elective outpatient colonoscopy were eligible for the study

排除标准

  • patients who had chronic kidney disease,
  • severe heart failure(New York Heart Association [NYHA] class III or IV)
  • uncontrolled hypertension (systolic pressure ≥170 mm Hg, diastolic pressure ≥100 mm Hg)
  • severe constipation
  • any bowel resection
  • significant gastroparesis, or
  • suspected bowel obstruction or perforation.

研究组 & 干预措施

PEG-Asc

Active Comparator

group 1 (PEG-Asc, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure

干预措施: PEG-Asc (Drug)

PEG-Asc

Active Comparator

group 1 (PEG-Asc, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure

干预措施: PEG-Asc with simethicone (Drug)

PEG-Asc with simethicone

Active Comparator

group 2 (PEG-Asc with simethicone, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure.Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.

干预措施: PEG-Asc (Drug)

PEG-Asc with simethicone

Active Comparator

group 2 (PEG-Asc with simethicone, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure.Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.

干预措施: PEG-Asc with simethicone (Drug)

结局指标

主要结局

the quality of the bowel preparation using Preparation Scale

时间窗: 20 minutes

Preparation Scale Preparation Scale

次要结局

  • Completeness of the bowel preparation(10 minutes)
  • the patient's tolerability[questionnaire](30 minutes before the colonoscopy)
  • the endoscopist's tolerability[Visual Analog Score for fatigue](10 minutes)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

In-Kyung Yoo

fellow

Korea University Anam Hospital

研究点 (1)

Loading locations...

相似试验